Thursday, June 20, 2024, 5:00 PM – 6:00 PM

What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer

A CME/MOC-Accredited Live Webinar

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, June 20th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM

Faculty
Kevin Kalinsky, MD, MS
Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Glenn Family Breast Center
Director, Division of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Heather McArthur, MD, MPH
Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Merck.

Thursday, June 20, 2024
5:00 PM – 6:00 PM
Live CME/MOC-accredited webinar

A detailed agenda will be made available in the coming weeks. Discussion Topics

  • Incorporating Antibody-Drug Conjugates into the Management of Metastatic Triple-Negative Breast Cancer (TNBC)
  • Current Role of Immunotherapy and PARP Inhibitors in the Management of TNBC

Target Audience
This activity is intended for medical oncologists, breast surgeons, hematology-oncology fellows, radiation oncologists and other healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available research data evaluating anti-PD-1/PD-L1 antibody-based approaches for patients with localized triple-negative breast cancer (TNBC), and consider the role of these strategies in clinical practice.
  • Review available research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive metastatic TNBC (mTNBC), and use this information to identify patients who may be appropriate for this approach.
  • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure, HER2-low status) and individual preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or for those who experience disease progression on front-line chemoimmunotherapy.
  • Appreciate available clinical trial data with approved antibody-drug conjugates for patients with mTNBC to determine how to optimally incorporate these agents into current treatment algorithms.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with, and ongoing clinical trials evaluating other novel agents and treatment strategies under development for TNBC.

CME Credit Form
A CME credit form link will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY
To be announced.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc,
R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Merck.